Overview

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Status:
RECRUITING
Trial end date:
2027-07-09
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565 in participants with SLE
Phase:
PHASE1
Details
Lead Sponsor:
Novartis Pharmaceuticals